FDA Inspection Readiness for Compounding Pharmacies & Outsourcing Facilities
Compounding pharmacies and outsourcing facilities operate under increasing scrutiny from both State Boards of Pharmacy and the FDA. Whether you are a 503A compounding pharmacy or a registered 503B outsourcing facility, inspection readiness requires more than documentation — it requires defensible systems.
Compliance Insight provides expert 503A and 503B compounding compliance consulting focused on FDA inspection readiness, sterile compounding oversight, and scalable quality management systems.
We translate regulatory expectations into operational confidence.
FDA Inspection Readiness for 503A & 503B Facilities
FDA inspections of compounding operations are detailed, system-focused, and risk-based. Investigators routinely evaluate:
- Aseptic processing controls
- Environmental monitoring programs and data trending
- Contamination control strategy
- Deviation investigations and CAPA effectiveness
- Batch record documentation and release controls
- Data integrity practices
- Bulk drug substance compliance
- “Essentially a copy” determinations
- Labeling, Marketing, Websites
Our gap assessments evaluate your operation through the lens of the State Board of Pharmacy and FDA investigators — not generic checklists. We provide prioritized, risk-based action plans that reduce regulatory exposure and strengthen inspection defensibility.
For executives and quality leaders, this means fewer surprises and more predictable outcomes.
Sterile & Non-Sterile Compounding Compliance Support
Sterile compounding compliance demands disciplined environmental control, validated cleaning programs, and consistent personnel qualification.
We support:
- Environmental monitoring design, trending, and excursion response
- Media fill and personnel qualification programs
- Cleaning validation and disinfectant rotation strategies
- Contamination control documentation
- Non-sterile compounding documentation scaling
- cGMP-aligned systems for 503 A & 503B outsourcing facilities
- Aseptic technique training
For 503A pharmacies, we right-size systems to meet regulatory expectations without unnecessary infrastructure burden.
For 503B facilities, we align quality systems with FDA CGMP requirements and inspection trends.
Compounding Quality Management Systems (QMS)
A defensible quality management system is foundational to both 503A and 503B compliance.
We design and strengthen:
- SOP frameworks and governance
- Master batch record structures
- Change control systems
- Deviation investigation and CAPA programs
- Supplier qualification oversight
- Complaint handling and adverse event processes
Our focus is not documentation volume — it is documentation defensibility. Systems must be executable, sustainable, and inspection-ready.
Regulatory Strategy for High-Risk Compounding Areas
Compounding compliance includes complex regulatory interpretations that demand strategic clarity.
We provide guidance in areas such as:
- Bulk drug substance eligibility
- “Essentially a copy” analysis and documentation
- “Office Use” policies
- Compounding boundaries
- FDA inspection response strategy
- Reportable Adverse Events
Our recommendations are grounded in regulatory precedent and enforcement patterns — ensuring your decisions align with both regulatory text and regulatory intent.
Select Services & Capabilities
Quality Management
Clinical Trial Design and Evaluation
GMP Compliance
FDA cGMP Compliance
Regulatory Applications & Submissions
Medical Device Biocompatibility
Regulatory Strategy
FDA and Advisory Meetings
Author, Review and Publish Applications and Amendments
GLP and GCP
Pharmacology/Toxicology
Immunogenicity Assessment
U.S. Agent Services
Auditing & Verification
Market Authorizations
Adverse Event Reporting